Evaluating the Safety and Immune Response to a Live H7N9 Influenza Virus Vaccine Followed by an Inactivated H7N9 Influenza Virus Vaccine, Given at Varying Intervals

Influenza A Virus, H7N9 Subtype Clinical Trial

Official title:

Phase 1 Evaluation of the Optimal Interval Between Priming With a Live Influenza A Vaccine H7N9 (6-2) AA ca Recombinant (A/Anhui/1/2013 (H7N9) x A/Ann Arbor/6/60 ca), a Live Attenuated Virus Vaccine Candidate for Prevention of Influenza H7N9 Disease Followed by Boost With a Non-adjuvanted Inactivated H7N9 Influenza Vaccine

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02151344
• Other study ID #: CIR 293
• Status: Completed
• Phase: Phase 1
• First received: May 28, 2014
• Last updated: March 26, 2015
• Start date: May 2014
• Est. completion date: February 2015

Study information

• Verified date: March 2015
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

H7N9 viruses have caused a recent outbreak of severe illness in humans in China. The purpose of this study is to evaluate the safety and immune response of an H7N9 A/Anhui/13 ca influenza virus vaccine followed by an inactivated subvirion H7N9 vaccine at varying intervals.

Description:

H7N9 avian influenza (AI) viruses have been responsible for a recent outbreak of illness in humans in China, which was associated with severe respiratory illnesses resulting in acute respiratory distress syndrome (ARDS) and intensive care unit (ICU) admissions. The purpose of this study is to evaluate the safety, infectivity, and immunogenicity of a live attenuated H7N9 A/Anhui/13 cold adapted (ca) influenza virus vaccine followed by a boost with an inactivated subvirion H7N9 vaccine at varying intervals.

This study will enroll participants into five cohorts. Participants in Cohorts 1, 2, 3, and 4 will be admitted to an isolation unit on Study Day -2. On Study Day 0, participants will receive one dose of the H7N9 A/Anhui/13 ca influenza virus vaccine via a nose spray device. While in the isolation unit, participants will undergo a physical examination and nasal wash each day, and a blood collection on select days. Participants will remain in the isolation unit for at least 9 days after receiving the vaccine, but possibly longer, depending on their test results.

Participants in Cohorts 1 and 2 will return to the isolation unit 4 to 8 weeks after receiving the first vaccine (at approximately Day 28). They will receive the second dose of the H7N9 A/Anhui/13 ca influenza virus vaccine and repeat all of the same procedures that occurred after the first vaccination.

Participants will then receive one dose of the inactivated subvirion H7N9 vaccine 1 month (Cohort 1) or 2 months (Cohort 2) after receiving the second vaccine.

Participants in Cohorts 3 and 4 will receive the inactivated subvirion H7N9 vaccine either 1 month (Cohort 4) or 2 months (Cohort 3) after receiving one dose of the live attenuated vaccine. For Cohorts 1-4, participants study visits will occur 7, 14, 28, and 90 days after receiving the vaccine and will include a medical history review, physical examination, and blood collection at select visits.

Participants in Cohort 5 will receive one dose of the inactivated subvirion H7N9 vaccine at Day 0 and one dose at Day 28. Study visits will occur on Days 0, 7, 28, 35, 42, 56, and 118, and will include blood collections and physical examinations. Participants in Cohort 5 will not be admitted to the isolation unit.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: February 2015
• Est. primary completion date: February 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Adult males and non-pregnant females between 18 years and 49 years of age, inclusive. Children will not be recruited or enrolled in this study because they are not in the apparent risk group, for safety considerations, and because of the need for isolation.

• General good health, without significant medical illness, physical examination findings, or significant laboratory abnormalities as determined by the investigator

• Agree to storage of blood specimens for future research

• Available for the duration of the trial

• Willingness to participate in the study as evidenced by signing the informed consent document

• Female participants of childbearing potential must agree to use effective birth control methods for the duration of the study (for example, pharmacologic contraceptives including oral, parenteral, and transcutaneous delivery; condoms with spermicide; diaphragm with spermicide; intrauterine device; abstinence from heterosexual intercourse; surgical sterilization). All female participants will be considered being of childbearing potential except those who have undergone hysterectomy and those in whom menopause occurred at least 1 year prior to the study.

Exclusion Criteria:

• Pregnancy, as determined by a positive human choriogonadotropin (beta-HCG) test

• Currently breastfeeding

• Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies including urine testing

• Behavioral or cognitive impairment or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and cooperate with the study protocol

• Previous enrollment in an H7 influenza vaccine trial or in any study of an avian influenza vaccine

• Seropositive to the H7N9 influenza A virus (serum HAI titer greater than 1:8)

• Positive urine drug toxicology test indicating narcotic use/dependency

• Have medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months

• Other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol

• History of anaphylaxis

• Allergy to oseltamivir as determined by participant report

• Current diagnosis of asthma or reactive airway disease (within the past 2 years)

• History of Guillain-Barré Syndrome

• Positive enzyme-linked immunosorbent assay (ELISA) and confirmatory test (e.g., Western blot or HIV-1/HIV-2 differentiation assay) for human immunodeficiency virus-1 (HIV-1)

• Positive ELISA and confirmatory test (e.g., recombinant immunoblot assay) for hepatitis C virus (HCV)

• Positive hepatitis B virus surface antigen (HBsAg) by ELISA

• Known immunodeficiency syndrome

• Use of corticosteroids (excluding topical preparations) or immunosuppressive drugs within 30 days prior to vaccination

• Receipt of a live vaccine within 4 weeks or a killed vaccine within 2 weeks prior to study vaccination

• History of asplenia

• Body mass index (BMI) greater than 40

• Receipt of blood or blood-derived products (including immunoglobulin) within 6 months prior to study vaccination

• Current smoker unwilling to stop smoking for the duration of the study. More information on this criterion is available in the protocol.

• Travel to the Southern Hemisphere within 14 days prior to study vaccination

• Travel on a cruise ship within 14 days prior to study vaccination

• Receipt of another investigational vaccine or drug within 30 days prior to study vaccination

• History of hypersensitivity to any component of the investigational product including egg or egg protein, or serious, life threatening, or severe reactions to previous influenza vaccinations

• Individuals who use intranasal medications chronically

• Receipt of antiviral therapy or antiviral agents within 48 hours prior to receipt of investigational product

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza A Virus, H7N9 Subtype
• Influenza, Human

Intervention

Biological:
• H7N9 A/Anhui/13 ca influenza virus vaccine
Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
• Inactivated subvirion H7N9 vaccine
Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.

Locations

Country	Name	City	State
United States	Johns Hopkins Bayview Medical Center	Baltimore	Maryland

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of the ability of the pLAIV vaccine to induce priming by assessing the response to a subsequent dose of pIIV		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No
Primary	Measurement of the optimal interval between the priming with pLAIV and the subsequent boost with pIIV		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No
Primary	Determination of whether 1 dose or 2 doses of pLAIV followed by a pIIV boost is sufficient to induce an optimal immune response		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No
Primary	Frequency of vaccine-related reactogenicity events (REs) for 2 doses of pLAIV vaccine followed by a single dose of inactivated pIIV and compare to 2 doses of pIIV alone		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	Yes
Primary	Frequency of other adverse events (AEs) for 2 doses of pLAIV vaccine followed by a single dose of inactivated pIIV and compare to 2 doses of pIIV alone		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	Yes
Secondary	Number of vaccinees infected with the H7N9 Anhui 2013/AA ca recombinant vaccine candidate	Infection is defined as recovery of vaccine virus from nasal wash, detection of virus in nasal wash by rRT-PCR, and/or a greater than or equal to 4-fold rise in antibody titer.	Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No
Secondary	Measurement of the amount of vaccine virus shed by each recipient		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No
Secondary	Measurement of amount of serum and nasal wash antibody induced by the vaccine		Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No
Secondary	Capacity of the H7N9 Anhui 2013/AA ca recombinant vaccine candidate to elicit HAI and neutralizing antibodies to future H7 influenza viruses	Includes the development of a serum bank	Measured through participants' last study visit: 90 days after receiving the last vaccine (Cohorts 1-4) or Day 118 (Cohort 5)	No